EMBO Gold Medal 2004 goes to Spanish scientist

September 30, 2004

The 2004 winner of the EMBO Gold Medal is María Blasco, Director of the Molecular Oncology Program at the Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid. The EMBO Gold Medal is awarded annually to an outstanding young scientist for exceptional research carried out within Europe. Maria Blasco receives the award in recognition of her landmark work in the area of telomeres*. The scientist's research has had a groundbreaking impact on cancer research and received wide recognition in the field. The medal will be presented to the winner at the EMBO Members Meeting, "Frontiers of Molecular Biology", in Vienna on October 15, 2004.

The EMBO Gold Medal highlights the high standards being reached in molecular biology in Europe. Awarded annually to a scientist under 40 years of age, the prize brings the very best young scientists in Europe to the attention of a global audience. Presented for the first time in 1986, the EMBO Gold Medal has had many notable recipients. On hearing the news of her selection, the 2004 winner, María Blasco, commented:

"I'm honoured to accept this prestigious award. It's extremely satisfying to gain the recognition of the wider scientific community for my group's research efforts. I'm also delighted to be the first Spanish scientist to receive this prize and as a female scientist, I hope my achievement will inspire other women in science to persevere in their career."

Frank Gannon, Executive Director of EMBO said:

"EMBO is about advancing the biosciences in Europe. This means maintaining quality and momentum in research. One way of doing this is to put a spotlight on the best molecular biologists in Europe. The EMBO Gold Medal highlights the accomplishments of young researchers, showing just what can and is being achieved. María is a fine example of this. Her contribution to cancer research is unquestionable and her unstinting dedication makes her the ideal role model for other young researchers."

María Blasco - Background and research

Born in Alicante, Spain, María Blasco is currently the Director of the Molecular Oncology Programme at the Spanish National Cancer Centre (CNIO) in Madrid. In 1993, the scientist obtained her Ph.D. in Biochemistry and Molecular Biology at the University Autónoma of Madrid, where she made significant contributions to the structure function of a viral DNA polymerase involved in the replication of DNA ends.

Blasco's next move took her to Cold Spring Harbor Laboratory in New York City, where she investigated telomeres and telomerase. The scientist's research led to the landmark discovery of the mammalian telomerase RNA component. Subsequently Blasco knocked out the telomerase RNA in the mouse producing a powerful tool to understand the role of telomerase on cancer and aging.

In 1997, Blasco started her own research group in mammalian telomeres and telomerase at the National Centre of Biotechnology in Madrid. Most recently, the scientist moved her group to the Spanish National Cancer Centre (CNIO), where she now heads up the Molecular Oncology Programme. The research interests of Blasco's group have been diverse - not only connecting telomeres to DNA repair and the cell cycle but also to chromatin epigenetics.

Recent discoveries

Most recently, the research group produced the first characterization of mammalian telomeric heterochromatin and the activities that regulate it. Other recent groundbreaking contributions to cancer research include generation of the first telomerase transgenic mice - showing them to be tumour-prone; demonstration of interplay between the status of the retinoblastoma family of proteins and the length of the telomeres; and demonstration that telomere maintenance requires both telomerase activity and homologous recombination.

Since 1997, María Blasco has published more than 65 papers on telomere research in publications such as Cell, Nature Genetics, Molecular and Cellular Biology, and The EMBO Journal. The scientist has also received a number of international distinctions for her research. She was elected an EMBO member in 2000 and received the Swiss Bridge Award for Research in Cancer in the same year. In 2002, Blasco received the ELSO Early Career Award. Most recently, Blasco was honoured with the Josef Steiner Cancer Research Award and the Universalia Research Award in 2003 and the Carcinogenesis Young Investigator Award in 2004.

* Telomeres are the physical ends of chromosomes and have important functions, primarily in the protection, replication, and stabilization of the chromosome ends.
-end-
About the Centro Nacional de Investigaciones Oncológicas (CNIO)

The CNIO or the Spanish National Cancer Centre was founded in 1998 by the Salud Carlos III Institute of Health with support from the Spanish Ministry of Health. The mission of the CNIO is to bring the best research and the latest technology in the field of cancer to the Spanish National Health System. The CNIO is one of the few European cancer centres to allocate resources to both basic and applied research in an integrated fashion, thus supporting the interaction of basic research programmes with those of molecular diagnostics and drug discovery. www.cnio.es

About the European Molecular Biology Organization (EMBO)

EMBO promotes biosciences in Europe. The organisation supports transnational mobility, training and exchange at all stages of the scientific career through initiatives such as fellowships, courses and workshops. Founded in 1964, an example of EMBO's early impact was its establishment of the well-known laboratory, EMBL. EMBO elects new members annually on the basis of proven excellence in research. Today the organization has around 1200 members in Europe and approximately 100 associate members worldwide including some 36 Nobel Laureates. www.embo.org

Contact
EMBO
Lindsay Johnson
Communications Officer
EMBO
Postfach 102240
D-69012 Heidelberg
Germany
Tel: 49-6221-8891-108
Fax: 49-6221-8891-210
lindsay.johnson@embo.org

CNIO (for María Blasco)
Amanda Wren
Director of International Communications
Centro Nacional de Investigaciones Oncológicas (CNIO)
Spanish National Cancer Centre
C/ Melchor Fernández Almagro, 3
28029 Madrid
Spain
Tel: 34-91-224-6985
Fax: 34-91-224-6981
awren@cnio.es
Mb: 34-60-938-4526

European Molecular Biology Laboratory

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.